Focused On-demand Library for Ribosome maturation protein SBDS

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Shwachman-Bodian-Diamond syndrome protein

Alternative UPACC:

Q9Y3A5; A8K0P4; Q96FX0; Q9NV53


The Ribosome maturation protein SBDS, also known as Shwachman-Bodian-Diamond syndrome protein, plays a crucial role in ribosome biogenesis. It is essential for the assembly of mature ribosomes, facilitating the GTP-dependent release of EIF6 from 60S pre-ribosomes, thereby activating ribosomes for translation competence. This protein is also involved in protein synthesis, cellular stress resistance, DNA damage response, and cell proliferation.

Therapeutic significance:

Given its pivotal role in ribosome biogenesis and cellular processes, the Ribosome maturation protein SBDS is closely associated with Shwachman-Diamond syndrome 1, a disorder marked by hematopoietic abnormalities, exocrine pancreatic dysfunction, and skeletal dysplasia. Understanding the role of Ribosome maturation protein SBDS could open doors to potential therapeutic strategies for this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.